jCyte

Focus: jCyte is a public biotechnology company developing progenitor cell-based therapies focused on retinal degenerative diseases, particularly retinitis pigmentosa. The company operates as a specialized player in the ophthalmology space with a proprietary human retinal progenitor cell platform.

Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$30M

Open Jobs

About jCyte

AI assessmentNot Hiring

No open roles listed right now. Follow jCyte to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

human retinal progenitor cells

Retinitis Pigmentosa (RP)

PHASE_1_2

Clinical Trials (1)

NCT02320812Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

Phase 1/2

Help build intelligence for jCyte

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Rare opportunity to work on cutting-edge progenitor cell technology in ophthalmology, a field with significant unmet medical need
Public company status provides potential for equity upside and established corporate infrastructure despite early-stage pipeline
Focused pipeline allows deep expertise development in regenerative medicine and cell therapy manufacturing

Watch Out For

Only 1 active hiring role (CTF) signals minimal expansion and limited career mobility within organization
No marketed products and early-stage pipeline (Phase 1/2) means revenue is years away, creating cash burn risk and potential restructuring
Lack of public financial data, publication record (0 publications), and limited pipeline transparency raise questions about scientific progress and company momentum

Generated by Claude from jCyte's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

human retinal progenitor cells

Retinitis Pigmentosa

PHASE_2

Clinical Trials (1)

NCT03073733Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

Phase 2

human retinal progenitor cells

Retinitis Pigmentosa

PHASE_2

Clinical Trials (1)

NCT06912633Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

Phase 2

human retinal progenitor cells

Retinitis Pigmentosa

PHASE_2

Clinical Trials (1)

NCT04604899Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo